Related Experiment Video
Updated: May 26, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
Tackling endothelial dysfunction by modulating NOS uncoupling: new insights into its pathogenesis and therapeutic
Rinrada Kietadisorn1, Rio P Juni, An L Moens
1Maastricht Univ. Medical Centre, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
American Journal of Physiology. Endocrinology and Metabolism
|December 15, 2011
Summary
Endothelial nitric oxide synthase (eNOS) uncoupling reduces nitric oxide (NO) bioavailability, contributing to endothelial dysfunction. Modulating eNOS offers therapeutic potential for vascular diseases.
Area of Science:
- Cardiovascular Biology
- Biochemistry
- Pathophysiology
Background:
- Endothelial nitric oxide synthase (eNOS) produces nitric oxide (NO), vital for vascular pressure and endothelial function.
- eNOS uncoupling, leading to reduced NO and increased superoxide, underlies endothelial dysfunction in various diseases like atherosclerosis and diabetes.
Purpose of the Study:
- To review the critical role of eNOS uncoupling in endothelial dysfunction pathogenesis.
- To explore therapeutic strategies targeting eNOS modulation for improved endothelial function.
Main Methods:
- Literature review of eNOS function, uncoupling mechanisms, and related diseases.
- Analysis of current and potential therapeutic interventions for eNOS modulation.
Main Results:
- eNOS uncoupling is a key factor in endothelial dysfunction across multiple pathologies.
- Stabilizing eNOS, enhancing its components, or reversing uncoupling are promising therapeutic avenues.
Conclusions:
- Targeting eNOS uncoupling presents a significant therapeutic opportunity for treating endothelial dysfunction.
- Further research into eNOS modulation could lead to novel treatments for vascular conditions.
Related Concept Videos
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...